Bimekizumab: Dual IL-17A/F Inhibition

Overview / Definition Bimekizumab is a humanized monoclonal antibody that specifically targets and inhibits interleukin 17A (IL-17A) and interleukin 17F (IL-17F). This dual inhibition provides a significant therapeutic approach for patients with chronic inflammatory conditions, particularly moderate to severe plaque psoriasis. By blocking these pro-inflammatory cytokines, bimekizumab aims to reduce the inflammatory pathways that contribute to skin lesions and systemic symptoms. Epidemiology Psoriasis affects approximately 2-3% of the global population, with significant prevalence in adults. In the United States alone, it is estimated that over 8 million individuals live with this chronic disease. The incidence of psoriasis is higher in certain populations, including individuals with a family history of the disease, and it often presents in early adulthood, although it can manifest at any age. Pathophysiology / Mechanism The pathophysiology of psoriasis is intricately linked to dysregulation of the immune system, particularly involving T-helper cell 17 (Th17) pathways. IL-17A and IL-17F are cytokines produced by Th17 cells that play critical roles in the inflammatory process, promoting keratinocyte proliferation and the inflammatory response in the skin. IL-17A stimulates keratinocyte activation, leading to enhanced proliferation and reduced apoptosis. IL-17F works synergistically with IL-17A to amplify inflammatory responses. Bimekizumab’s dual inhibition of IL-17A and IL-17F leads to a robust reduction in inflammatory pathways. Clinical Presentation Patients with psoriasis typically present with well-defined erythematous plaques covered with silvery-white scales. Common sites include: Elbows Knees Scalp Lumbar region Nails (nail dystrophy) Intergluteal cleft and genital areas in inverse psoriasis Patients may also experience associated symptoms such as pruritus, burning, and stinging sensations. Psoriasis can be associated with comorbidities such as psoriatic arthr